vs
Side-by-side financial comparison of FORUM ENERGY TECHNOLOGIES, INC. (FET) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
FORUM ENERGY TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($208.7M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). FORUM ENERGY TECHNOLOGIES, INC. runs the higher net margin — 2.2% vs 1.6%, a 0.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 3.2%). Over the past eight quarters, FORUM ENERGY TECHNOLOGIES, INC.'s revenue compounded faster (0.8% CAGR vs -0.2%).
Forum Energy Technologies is an American oilfield products company that provides products and services to the oil and gas, and renewable industries worldwide.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FET vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $208.7M | $177.4M |
| Net Profit | $4.5M | $2.9M |
| Gross Margin | 29.2% | — |
| Operating Margin | 5.3% | 3.9% |
| Net Margin | 2.2% | 1.6% |
| Revenue YoY | 3.2% | 5.0% |
| Net Profit YoY | 300.4% | — |
| EPS (diluted) | $0.39 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $208.7M | $177.4M | ||
| Q4 25 | $202.2M | $196.9M | ||
| Q3 25 | $196.2M | $179.5M | ||
| Q2 25 | $199.8M | $181.1M | ||
| Q1 25 | $193.3M | $168.9M | ||
| Q4 24 | $201.0M | $187.3M | ||
| Q3 24 | $207.8M | $168.6M | ||
| Q2 24 | $205.2M | $178.0M |
| Q1 26 | $4.5M | $2.9M | ||
| Q4 25 | $2.1M | — | ||
| Q3 25 | $-20.6M | $5.4M | ||
| Q2 25 | $7.7M | $-4.8M | ||
| Q1 25 | $1.1M | $4.8M | ||
| Q4 24 | $-103.5M | — | ||
| Q3 24 | $-14.8M | $-143.5M | ||
| Q2 24 | $-6.7M | $18.9M |
| Q1 26 | 29.2% | — | ||
| Q4 25 | 30.2% | 79.5% | ||
| Q3 25 | 20.5% | 80.9% | ||
| Q2 25 | 29.7% | 77.4% | ||
| Q1 25 | 30.2% | 79.7% | ||
| Q4 24 | 31.1% | 78.7% | ||
| Q3 24 | 31.6% | 76.9% | ||
| Q2 24 | 30.7% | 75.1% |
| Q1 26 | 5.3% | 3.9% | ||
| Q4 25 | 6.3% | 1.2% | ||
| Q3 25 | -3.1% | 3.5% | ||
| Q2 25 | 7.4% | 4.7% | ||
| Q1 25 | 4.6% | 1.2% | ||
| Q4 24 | -53.1% | 13.2% | ||
| Q3 24 | 4.3% | -82.8% | ||
| Q2 24 | 3.9% | 15.9% |
| Q1 26 | 2.2% | 1.6% | ||
| Q4 25 | 1.0% | — | ||
| Q3 25 | -10.5% | 3.0% | ||
| Q2 25 | 3.9% | -2.7% | ||
| Q1 25 | 0.6% | 2.8% | ||
| Q4 24 | -51.5% | — | ||
| Q3 24 | -7.1% | -85.1% | ||
| Q2 24 | -3.3% | 10.6% |
| Q1 26 | $0.39 | $0.07 | ||
| Q4 25 | $0.25 | $0.05 | ||
| Q3 25 | $-1.76 | $0.12 | ||
| Q2 25 | $0.61 | $-0.11 | ||
| Q1 25 | $0.09 | $0.10 | ||
| Q4 24 | $-8.41 | $0.38 | ||
| Q3 24 | $-1.20 | $-3.11 | ||
| Q2 24 | $-0.54 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.5M | $144.3M |
| Total DebtLower is stronger | $153.7M | — |
| Stockholders' EquityBook value | $280.7M | $653.9M |
| Total Assets | $763.1M | $1.2B |
| Debt / EquityLower = less leverage | 0.55× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $37.5M | $144.3M | ||
| Q4 25 | $34.7M | $238.4M | ||
| Q3 25 | $31.7M | $246.3M | ||
| Q2 25 | $39.0M | $445.9M | ||
| Q1 25 | $31.1M | $493.6M | ||
| Q4 24 | $44.7M | $484.6M | ||
| Q3 24 | $33.3M | $453.8M | ||
| Q2 24 | $31.8M | $404.2M |
| Q1 26 | $153.7M | — | ||
| Q4 25 | $135.9M | $372.2M | ||
| Q3 25 | $140.0M | $376.7M | ||
| Q2 25 | $159.3M | $580.5M | ||
| Q1 25 | $171.4M | $583.4M | ||
| Q4 24 | $188.4M | $585.3M | ||
| Q3 24 | $231.5M | — | ||
| Q2 24 | $252.9M | — |
| Q1 26 | $280.7M | $653.9M | ||
| Q4 25 | $291.1M | $693.1M | ||
| Q3 25 | $297.3M | $727.2M | ||
| Q2 25 | $334.2M | $757.8M | ||
| Q1 25 | $320.0M | $798.5M | ||
| Q4 24 | $319.9M | $778.3M | ||
| Q3 24 | $443.5M | $749.6M | ||
| Q2 24 | $442.0M | $879.3M |
| Q1 26 | $763.1M | $1.2B | ||
| Q4 25 | $752.5M | $1.3B | ||
| Q3 25 | $770.1M | $1.3B | ||
| Q2 25 | $810.1M | $1.5B | ||
| Q1 25 | $790.1M | $1.6B | ||
| Q4 24 | $816.0M | $1.6B | ||
| Q3 24 | $973.7M | $1.5B | ||
| Q2 24 | $976.8M | $1.6B |
| Q1 26 | 0.55× | — | ||
| Q4 25 | 0.47× | 0.54× | ||
| Q3 25 | 0.47× | 0.52× | ||
| Q2 25 | 0.48× | 0.77× | ||
| Q1 25 | 0.54× | 0.73× | ||
| Q4 24 | 0.59× | 0.75× | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.57× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6M | — |
| Free Cash FlowOCF − Capex | $1.4M | — |
| FCF MarginFCF / Revenue | 0.7% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 0.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.6M | — | ||
| Q4 25 | $22.4M | $43.7M | ||
| Q3 25 | $22.9M | $60.8M | ||
| Q2 25 | $15.8M | $12.0M | ||
| Q1 25 | $9.3M | $35.5M | ||
| Q4 24 | $38.5M | $33.1M | ||
| Q3 24 | $25.6M | $53.9M | ||
| Q2 24 | $23.1M | $53.2M |
| Q1 26 | $1.4M | — | ||
| Q4 25 | $20.9M | $43.5M | ||
| Q3 25 | $21.5M | $57.0M | ||
| Q2 25 | $14.8M | $9.3M | ||
| Q1 25 | $7.2M | $26.9M | ||
| Q4 24 | $36.1M | $31.0M | ||
| Q3 24 | $24.3M | $49.8M | ||
| Q2 24 | $21.6M | $51.6M |
| Q1 26 | 0.7% | — | ||
| Q4 25 | 10.3% | 22.1% | ||
| Q3 25 | 10.9% | 31.7% | ||
| Q2 25 | 7.4% | 5.1% | ||
| Q1 25 | 3.7% | 15.9% | ||
| Q4 24 | 18.0% | 16.6% | ||
| Q3 24 | 11.7% | 29.6% | ||
| Q2 24 | 10.5% | 29.0% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | 0.8% | 0.1% | ||
| Q3 25 | 0.7% | 2.2% | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 1.1% | 5.1% | ||
| Q4 24 | 1.2% | 1.1% | ||
| Q3 24 | 0.6% | 2.4% | ||
| Q2 24 | 0.7% | 0.9% |
| Q1 26 | 0.36× | — | ||
| Q4 25 | 10.83× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 2.05× | — | ||
| Q1 25 | 8.31× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FET
| Drilling and Completions | $126.7M | 61% |
| Downhole | $50.6M | 24% |
| Production Equipment | $18.8M | 9% |
| Valve Solutions | $12.8M | 6% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
